Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Allakos Inc. (ALLK)

4.61   -0.12 (-2.54%) 03-24 16:00
Open: 4.68 Pre. Close: 4.73
High: 4.78 Low: 4.505
Volume: 757,314 Market Cap: 395(M)

Technical analysis

as of: 2023-03-24 4:23:55 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6.87     One year: 7.87
Support: Support1: 4.5    Support2: 3.74
Resistance: Resistance1: 5.88    Resistance2: 6.73
Pivot: 5.37
Moving Average: MA(5): 4.8     MA(20): 5.5
MA(100): 6.87     MA(250): 5.3
MACD: MACD(12,26): -0.5     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 4     %D(3): 4.5
RSI: RSI(14): 29.5
52-week: High: 8.72  Low: 2.53
Average Vol(K): 3-Month: 968 (K)  10-Days: 986 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ALLK ] has closed above bottom band by 12.2%. Bollinger Bands are 31.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.79 - 4.81 4.81 - 4.83
Low: 4.44 - 4.47 4.47 - 4.5
Close: 4.57 - 4.61 4.61 - 4.65

Company Description

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Headline News

Tue, 07 Mar 2023
Why Allakos Stock Was Heating Up Today - The Motley Fool

Tue, 07 Mar 2023
Piper Sandler Initiates Coverage of Allakos (ALLK) with Overweight ... - Nasdaq

Tue, 07 Mar 2023
Allakos Inc. (NASDAQ:ALLK) Short Interest Update - MarketBeat

Mon, 06 Mar 2023
Logos Global Management LP acquires a stake in Allakos Inc ... - Best Stocks

Mon, 06 Mar 2023
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results - Yahoo Finance

Sun, 05 Mar 2023
Logos Global Management LP Takes Position in Allakos Inc ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 86 (M)
Shares Float 42 (M)
% Held by Insiders 4.3 (%)
% Held by Institutions 91.3 (%)
Shares Short 3,570 (K)
Shares Short P.Month 2,700 (K)

Stock Financials

EPS -5.97
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.64
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -43.8
Return on Equity (ttm) -84.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.69
Qtrly Earnings Growth 0
Operating Cash Flow -280 (M)
Levered Free Cash Flow -172 (M)

Stock Valuations

PE Ratio -0.78
PEG Ratio -0.1
Price to Book value 1.26
Price to Sales 0
Price to Cash Flow -1.42

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.